Bormioli Pharma to Supply Carbon Capture PET Bottles for Chiesi’s Allergy Medication

• Bormioli Pharma partners with Chiesi to supply Carbon Capture PET bottles for allergy medications, marking the first use of these bottles in pharmaceuticals.

• Carbon Capture PET bottles reduce CO2 emissions by 21.9% compared to standard PET while maintaining similar performance and safety levels.

Bormioli Pharma, a pharmaceutical packaging provider, has entered into a long-term partnership with Chiesi, an international biopharmaceutical company. The collaboration will see Bormioli supply Carbon Capture PET bottles for Chiesi’s medication used to treat seasonal and perennial allergic rhinitis, as well as vasomotor rhinitis.

The Carbon Capture PET bottle will be used for pharmaceutical purposes for the first time. This packaging solution offers a 21.9% reduction in carbon emissions compared to traditional PET, without compromising safety or performance. According to the company, the levels of extractables in Carbon Capture PET match those of standard PET, making it a viable alternative for pharmaceutical use.

The bottles are manufactured by converting captured carbon emissions into BioMEG, a key molecule for PET production, through a fermentation process. The result is a recyclable material that performs similarly to conventional PET in terms of mechanical and physical properties.

Andrea Lodetti, CEO of Bormioli Pharma, highlighted the significance of the agreement with Chiesi, stating: “The agreement we’ve reached to supply one of their products with Carbon Capture PET bottles demonstrates both the performance and safety of these containers, as well as the growing commitment of the pharma industry towards sustainability.”